Table 2.

Cancer and treatment characteristics of KCS in Alberta, Canada, May 2010 (N = 703)

Variablen (%)
Months since diagnosis (Mean ± SD = 69.0 ± 55.5)
 <24145 (20.6)
 24—59199 (28.3)
 ≥60359 (51.1)
Type of kidney cancer
 Papillary140 (19.9)
 Nonpapillary246 (35.0)
 Do not know317 (45.1)
Lymph nodes involved
 Yes37 (5.3)
 No517 (73.5)
 Do not know149 (21.2)
Disease stage
 Localized574 (81.7)
 Metastatic88 (12.5)
 Do not know41 (5.8)
Location of metastases (N = 88)
 Lung47 (53.4)
 Lymph18 (20.5)
 Liver15 (17.0)
 Other28 (31.8)
Surgery treatment
 Yes684 (97.3)
 No19 (2.7)
Type of surgery (N = 684)
 Partial nephrectomy124 (18.1)
 Radical nephrectomy535 (78.2)
 Do not know25 (3.7)
Type of incision (N = 684)
 Laparoscopic206 (30.1)
 Open incision459 (67.1)
 Do not know19 (2.8)
Radiation treatment
 Yes27 (3.8)
 No676 (96.2)
Drug treatment
 Yes92 (13.1)
 No611 (86.9)
a Type of drug treatment (N = 92)
 Sunitinib (Sutent)53 (57.6)
 Sorafenib (Nexavar)18 (19.6)
 Everolimus (Afinitor)7 (7.6)
 Interferon7 (7.6)
 Do not know32 (34.8)
Current treatment status
 Completed treatment642 (91.3)
 Receiving treatment61 (8.7)
Recurrence
 Yes54 (7.7)
 No649 (92.3)
Current disease status
 Disease free610 (86.8)
 Existing disease93 (13.2)
  • acould check more than 1 response.